Vicky A Cameron

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8687881/publications.pdf

Version: 2024-02-01

104 papers 3,637 citations

35 h-index 56 g-index

105 all docs $\begin{array}{c} 105 \\ \\ \text{docs citations} \end{array}$

105 times ranked 6063 citing authors

#	Article	IF	CITATIONS
1	Identifying Candidate Protein Markers of Acute Kidney Injury in Acute Decompensated Heart Failure. International Journal of Molecular Sciences, 2022, 23, 1009.	4.1	O
2	Emerging microRNA biomarkers for acute kidney injury in acute decompensated heart failure. Heart Failure Reviews, 2021, 26, 1203-1217.	3.9	2
3	Impact of COVID-19 on health research in New Zealand: a case study of a research-intensive campus. Journal of the Royal Society of New Zealand, 2021, 51, S75-S85.	1.9	5
4	Fibrinogen and hemoglobin predict near future cardiovascular events in asymptomatic individuals. Scientific Reports, 2021, 11, 4605.	3.3	6
5	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	2.2	63
6	Insights into circular RNAs: their biogenesis, detection, and emerging role in cardiovascular disease. RNA Biology, 2021, 18, 2055-2072.	3.1	16
7	The Multi-Ethnic New Zealand Study of Acute Coronary Syndromes (MENZACS): Design and Methodology. Neurology International, 2021, 11, 84-97.	0.5	3
8	Vascular endothelial growth factor-A promoter polymorphisms, circulating VEGF-A and survival in acute coronary syndromes. PLoS ONE, 2021, 16, e0254206.	2.5	7
9	Novel and Annotated Long Noncoding RNAs Associated with Ischemia in the Human Heart. International Journal of Molecular Sciences, 2021, 22, 11324.	4.1	4
10	Association of Factor V Leiden With Subsequent Atherothrombotic Events. Circulation, 2020, 142, 546-555.	1.6	11
11	Hydrogen Sulfide Treatment Improves Post-Infarct Remodeling and Long-Term Cardiac Function in CSE Knockout and Wild-Type Mice. International Journal of Molecular Sciences, 2020, 21, 4284.	4.1	21
12	Contrasting signals of cardiovascular health among natriuretic peptides in subjects without heart disease. Scientific Reports, 2019, 9, 12108.	3.3	7
13	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	3.6	17
14	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	3.6	22
15	Combining Circulating MicroRNA andÂNT-proBNP to Detect and CategorizeÂHeart Failure Subtypes. Journal of the American College of Cardiology, 2019, 73, 1300-1313.	2.8	68
16	Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. European Heart Journal, 2018, 39, 1770-1780.	2.2	194
17	Diabetes induces the activation of pro-ageing miR-34a in the heart, but has differential effects on cardiomyocytes and cardiac progenitor cells. Cell Death and Differentiation, 2018, 25, 1336-1349.	11.2	47
18	New Insights into Cardiac and Vascular Natriuretic Peptides: Findings from Young Adults Born with Very Low Birth Weight. Clinical Chemistry, 2018, 64, 363-373.	3.2	16

#	Article	IF	Citations
19	Exploring perceptions of a rheumatoid arthritisâ€specific smoking cessation programme. Musculoskeletal Care, 2018, 16, 74-81.	1.4	7
20	Copy number variants implicate cardiac function and development pathways in earthquake-induced stress cardiomyopathy. Scientific Reports, 2018, 8, 7548.	3.3	8
21	Plasma levels of soluble VEGF receptor isoforms, circulating pterins and VEGF system SNPs as prognostic biomarkers in patients with acute coronary syndromes. BMC Cardiovascular Disorders, 2018, 18, 169.	1.7	12
22	Genomic medicine must reduce, not compound, health inequities: the case for hauora-enhancing genomic resources for New Zealand. New Zealand Medical Journal, 2018, 131, 81-89.	0.5	13
23	Hydrogen sulfide acts as a pro-inflammatory mediator in rheumatic disease. International Journal of Rheumatic Diseases, 2017, 20, 182-189.	1.9	31
24	Efficacy of a Rheumatoid Arthritis–Specific Smoking Cessation Program: A Randomized Controlled Pilot Trial. Arthritis Care and Research, 2017, 69, 28-37.	3.4	24
25	Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathy. Cardiovascular Research, 2017, 113, 90-101.	3.8	71
26	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	11.4	84
27	Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	28
28	Living in areas with different levels of earthquake damage and association with risk of cardiovascular disease: a cohort-linkage study. Lancet Planetary Health, The, 2017, 1, e242-e253.	11.4	21
29	Metabolic and Blood Pressure Effects of Walnut Supplementation in a Mouse Model of the Metabolic Syndrome. Nutrients, 2017, 9, 722.	4.1	13
30	Vitamin C Status Correlates with Markers of Metabolic and Cognitive Health in 50-Year-Olds: Findings of the CHALICE Cohort Study. Nutrients, 2017, 9, 831.	4.1	77
31	Cardiac CRFR1 Expression Is Elevated in Human Heart Failure and Modulated by Genetic Variation and Alternative Splicing. Endocrinology, 2016, 157, 4865-4874.	2.8	14
32	Developing a Tailored Smoking Cessation Intervention for Rheumatoid Arthritis Patients. Musculoskeletal Care, 2016, 14, 2-14.	1.4	11
33	Identifying Barriers to Smoking Cessation in Rheumatoid Arthritis. Arthritis Care and Research, 2015, 67, 607-615.	3.4	29
34	Higher prevalence of left ventricular hypertrophy in two MÄori cohorts: findings from the Hauora Manawa/Community Heart Study. Australian and New Zealand Journal of Public Health, 2015, 39, 26-31.	1.8	5
35	Ethnic-Specific Normative Reference Values for Echocardiographic LAÂand LV Size, LV Mass, and Systolic Function. JACC: Cardiovascular Imaging, 2015, 8, 656-665.	5.3	182
36	Chronic Urocortin 2 Administration Improves Cardiac Function and Ameliorates Cardiac Remodeling After Experimental Myocardial Infarction. Journal of Cardiovascular Pharmacology, 2015, 65, 269-275.	1.9	15

#	Article	IF	CITATIONS
37	The New Zealand 1986 very low birth weight cohort as young adults: mapping the road ahead. BMC Pediatrics, 2015, 15, 90.	1.7	22
38	Circulating MicroRNAs as Biomarkers in Coronary Heart Disease and Heart Failure. MicroRNA Diagnostics and Therapeutics, 2014, $1, \dots$	0.0	1
39	Single nucleotide polymorphisms in arrhythmia genes modify the risk of cardiac events and sudden death in long QT syndrome. Heart Rhythm, 2014, 11, 76-82.	0.7	53
40	Circulating miR-323-3p and miR-652: Candidate markers for the presence and progression of acute coronary syndromes. International Journal of Cardiology, 2014, 176, 375-385.	1.7	40
41	Broken heart syndrome â€" Is it a psychosomatic disorder?. Journal of Psychosomatic Research, 2014, 77, 158-160.	2.6	12
42	Genetic Polymorphism rs6922269 in the MTHFD1L Gene Is Associated with Survival and Baseline Active Vitamin B12 Levels in Post-Acute Coronary Syndromes Patients. PLoS ONE, 2014, 9, e89029.	2.5	12
43	Association Between the Chromosome 9p21 Locus and Angiographic Coronary Artery Disease Burden. Journal of the American College of Cardiology, 2013, 61, 957-970.	2.8	58
44	The Singapore Heart Failure Outcomes and Phenotypes (SHOP) Study and Prospective Evaluation of Outcome in Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PEOPLE) Study: Rationale and Design. Journal of Cardiac Failure, 2013, 19, 156-162.	1.7	61
45	Impact of age, phenotype and cardioâ€renal function on plasma <scp>C</scp> â€type and <scp>B</scp> â€type natriuretic peptide forms in an adult population. Clinical Endocrinology, 2013, 78, 783-789.	2.4	41
46	Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. European Journal of Heart Failure, 2013, 15, 1138-1147.	7.1	147
47	Hyperuricaemia and gout in <scp>N</scp> ew <scp>Z</scp> ealand rural and urban <scp>M</scp> Äori and nonâ€ <scp>M</scp> Äori communities. Internal Medicine Journal, 2013, 43, 678-684.	0.8	25
48	Genetic variation in the renin–angiotensin–aldosterone system is associated with cardiovascular risk factors and early mortality in established coronary heart disease. Journal of Human Hypertension, 2013, 27, 237-244.	2.2	20
49	Generation and characterization of a mouse model of the metabolic syndrome: apolipoprotein E and aromatase double knockout mice. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E576-E584.	3.5	15
50	Association between endothelin type A receptor haplotypes and mortality in coronary heart disease. Personalized Medicine, 2012, 9, 341-349.	1.5	2
51	A cohort study comparing cardiovascular risk factors in rural MÄori, urban MÄori and non-MÄori communities in New Zealand. BMJ Open, 2012, 2, e000799.	1.9	27
52	The Chromosome 9p21.3 Coronary Heart Disease Risk Allele Is Associated with Altered Gene Expression in Normal Heart and Vascular Tissues. PLoS ONE, 2012, 7, e39574.	2.5	37
53	KCNE5 Polymorphism rs697829 is Associated with QT Interval and Survival in Acute Coronary Syndromes Patients. Journal of Cardiovascular Electrophysiology, 2012, 23, 319-324.	1.7	12
54	Loose tobacco, ethnicity, income and rurality. Australian and New Zealand Journal of Public Health, 2012, 36, 291-292.	1.8	1

#	Article	IF	CITATIONS
55	Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. Journal of Molecular and Cellular Cardiology, 2011, 50, 695-701.	1.9	53
56	A Kaupapa MÄori approach to a community cohort study of heart disease in New Zealand. Australian and New Zealand Journal of Public Health, 2011, 35, 249-255.	1.8	18
57	Community screening for cardiovascular risk factors and levels of treatment in a rural MÄori cohort. Australian and New Zealand Journal of Public Health, 2011, 35, 517-523.	1.8	12
58	Response to Letter Regarding Article, "B-Type Natriuretic Peptide Signal Peptide Circulates in Human Blood: Evaluation as a Potential Biomarker of Cardiac Ischemia― Circulation, 2011, 123, .	1.6	0
59	Genomic Risk Variants at 1p13.3, 1q41, and 3q22.3 Are Associated With Subsequent Cardiovascular Outcomes in Healthy Controls and in Established Coronary Artery Disease. Circulation: Cardiovascular Genetics, 2011, 4, 636-646.	5.1	35
60	<i>CYP1A1 MSP</i> I (T6235C) gene polymorphism is associated with mortality in acute coronary syndrome patients. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 193-198.	1.9	11
61	B-Type Natriuretic Peptide Signal Peptide Circulates in Human Blood. Circulation, 2010, 122, 255-264.	1.6	44
62	A Common Variant at Chromosome 9P21.3 Is Associated With Age of Onset of Coronary Disease but Not Subsequent Mortality. Circulation: Cardiovascular Genetics, 2010, 3, 286-293.	5.1	44
63	The common G-866A polymorphism of the UCP2 gene and survival in diabetic patients following myocardial infarction. Cardiovascular Diabetology, 2009, 8, 31.	6.8	16
64	Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during development. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 1175-1184.	3.8	35
65	Genomic selection of reference genes for real-time PCR in human myocardium. BMC Medical Genomics, 2008, 1, 64.	1.5	45
66	Angiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohort. American Heart Journal, 2008, 156, 752-758.	2.7	23
67	lle164 variant of β2â€adrenoceptor does not influence outcome in heart failure but may interact with β blocker treatment. European Journal of Heart Failure, 2008, 10, 55-59.	7.1	19
68	Transforming Growth Factor- \hat{l}^2 Blockade Down-Regulates the Renin-Angiotensin System and Modifies Cardiac Remodeling after Myocardial Infarction. Endocrinology, 2008, 149, 5828-5834.	2.8	68
69	Angiotensinogen M235T and T174M Gene Polymorphisms in Combination Doubles the Risk of Mortality in Heart Failure. Hypertension, 2007, 49, 322-327.	2.7	49
70	Association of the aldosterone synthase gene C-344T polymorphism with risk factors and survival in a post-myocardial infarction cohort. Journal of Human Hypertension, 2007, 21, 256-258.	2.2	4
71	Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. Journal of Molecular Endocrinology, 2007, 38, 245-257.	2.5	65
72	AMPD1 gene polymorphism and survival in patients with stable congestive heart failure. American Heart Journal, 2007, 153, e13.	2.7	5

#	Article	lF	CITATIONS
73	Plasma Concentrations of Myeloperoxidase Predict Mortality After Myocardial Infarction. Journal of the American College of Cardiology, 2007, 49, 1993-2000.	2.8	289
74	Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post–myocardial infarction patients. American Heart Journal, 2006, 152, 312-320.	2.7	23
75	Comparison of infarct-derived and control ovine cardiac myofibroblasts in culture: response to cytokines and natriuretic peptide receptor expression profiles. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H1952-H1958.	3.2	11
76	Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. European Heart Journal, 2006, 27, 2088-2098.	2.2	44
77	Angiotensin Type-1 Receptor A1166C Gene Polymorphism Correlates With Oxidative Stress Levels in Human Heart Failure. Hypertension, 2006, 47, 1155-1161.	2.7	52
78	Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovascular Research, 2005, 68, 109-117.	3.8	63
79	Amino-Terminal proCNP: A Putative Marker of Cartilage Activity in Postnatal Growth. Pediatric Research, 2005, 58, 334-340.	2.3	64
80	Integrated Hemodynamic, Hormonal, and Renal Actions of Urocortin 2 in Normal and Paced Sheep. Circulation, 2005, 112, 3624-3632.	1.6	90
81	Adriamycin disruption of the Shh-Gli pathway is associated with abnormalities of foregut development. Journal of Pediatric Surgery, 2004, 39, 1747-1753.	1.6	31
82	Absence of a NPR-A Gene Functional Deletion Allele in a Postmyocardial Infarction Cohort From New Zealand. Circulation Research, 2004, 94, .	4.5	3
83	Activation of NF-κB nuclear transcription factor by flow in human endothelial cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2003, 1642, 33-44.	4.1	34
84	Angiotensin-converting enzyme polymorphism (I/D) and coronary heart disease in young adults: Reply. Journal of the American College of Cardiology, 2003, 42, 1864.	2.8	0
85	Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. Journal of the American College of Cardiology, 2003, 41, 729-736.	2.8	65
86	Adrenomedullin and heart failure. Regulatory Peptides, 2003, 112, 51-60.	1.9	36
87	Minireview: Natriuretic Peptides during Development of the Fetal Heart and Circulation. Endocrinology, 2003, 144, 2191-2194.	2.8	138
88	Natriuretic peptide system in fetal heart and circulation. Journal of Hypertension, 2002, 20, 801-803.	0.5	1
89	Dendroaspis natriuretic peptide: endogenous or dubious?. Lancet, The, 2002, 359, 5-6.	13.7	39
90	Adrenomedullin expression in rat uterus is correlated with plasma estradiol. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E139-E146.	3.5	42

#	Article	IF	Citations
91	C-Type Natriuretic Peptide Expression in Olfactory Regions of Rat Brain Is Modulated by Acute Water Deprivation, Salt Loading and Central Angiotensin II. Neuroendocrinology, 2001, 73, 46-53.	2.5	10
92	Neurohormones in an ovine model of compensated postinfarction left ventricular dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 278, H731-H740.	3.2	21
93	Atrial (ANP) and Brain Natriuretic Peptide (BNP) Expression after Myocardial Infarction in Sheep: ANP Is Synthesized by Fibroblasts Infiltrating the Infarct ¹ . Endocrinology, 2000, 141, 4690-4697.	2.8	69
94	Atrial (ANP) and Brain Natriuretic Peptide (BNP) Expression after Myocardial Infarction in Sheep: ANP Is Synthesized by Fibroblasts Infiltrating the Infarct. Endocrinology, 2000, 141, 4690-4697.	2.8	17
95	Novel Sites of Adrenomedullin Gene Expression in Mouse and Rat Tissues1. Endocrinology, 1998, 139, 2253-2264.	2.8	101
96	Hemodynamic and hormonal effects of neutral endopeptidase inhibitor SCH 39370 in sheep Hypertension, 1991, 17, 643-651.	2.7	12
97	Intracerebroventricular Atrial Natriuretic Factor (ANF) Antiserum Inhibits Volume-Induced ANF in Sheep: Evidence for the Brain's Regulation of ANF Secretion*. Endocrinology, 1991, 129, 2225-2230.	2.8	17
98	Biological Actions of Cleaved Atrial Natriuretic Factor (ANF101–105/106–126) in Conscious Sheep. Journal of Cardiovascular Pharmacology, 1991, 17, 403-410.	1.9	7
99	Intracerebroventricular Atrial Natriuretic Peptide Infusion Augments the Adrenocorticotropin and Angiotensin II Responses to Hemorrhage in Sheep. Neuroendocrinology, 1990, 52, 589-594.	2.5	8
100	Evidence for Activation of Brain Atrial Natriuretic Factor During Acute Plasma Volume Expansion in Sheep*. Endocrinology, 1990, 127, 2587-2591.	2.8	3
101	Hormone and Hemodynamic Responses to Atrial Natriuretic Peptide in Conscious Sheep and Effect of Hemorrhage*. Endocrinology, 1988, 122, 407-414.	2.8	31
102	Effect of central naloxone on hormone and blood pressure responses to hemorrhage in conscious sheep. Life Sciences, 1987, 41, 571-578.	4.3	2
103	Intra-cerebroventricular captopril reduces plasma acth and vasopressin responses to hemorrhagic stress. Life Sciences, 1986, 38, 553-559.	4.3	26
104	Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis. Frontiers in Physiology, 0, 13, .	2.8	1